What are the biological consequences of ALCAM ectodomain shedding?

Proteolytic cleavage of the ALCAM extracellular domain is primarily mediated by metalloproteinases such as ADAM17 and MMP14. This shedding results in a transition from a pro-adhesive membrane-bound state to a migratory phenotype. High concentrations of the resulting soluble ALCAM (sALCAM) in biofluids often correlate with tumor invasiveness, as the loss of membrane anchors facilitates the detachment of malignant cells from the primary tumor mass.

How do alternative splice variants like ALCAM-Iso2 influence cancer progression?

ALCAM-Iso2 is a common splice variant characterized by a shorter stalk region due to the exclusion of exon 13. Research suggests that ALCAM-Iso2 is significantly more susceptible to enzymatic shedding than the standard ALCAM-Iso1. The resulting increase in sALCAM production disrupts stable homotypic interactions, thereby promoting cell motility and metastatic dissemination in cancers such as bladder carcinoma.

Is ALCAM expression restricted to pathological tissues?

No, ALCAM is physiologically expressed in a variety of healthy tissues, including epithelial cells, activated T cells, neurons, and fibroblasts. It plays essential roles in embryogenesis, hematopoiesis, and the stabilization of the immunological synapse. Pathological concern arises when there is a significant shift in its spatial localization (e.g., from membrane to cytoplasm) or an aberrant upregulation in specific cancer-initiating cells.

What role does glycosylation play in ALCAM's molecular weight and function?

Although the calculated molecular weight of the ALCAM protein backbone is approximately 65 kDa, it typically appears at 100-105 kDa on a Western blot due to extensive N-linked and O-linked glycosylation. These carbohydrate modifications are critical for its adhesive avidity; for instance, the presence of β1-6 branched N-glycans has been linked to increased metastatic potential in melanoma models.

How does the ALCAM-CD6 interaction affect immune signaling?

ALCAM functions as a high-affinity ligand for CD6, a marker expressed on the surface of T cells. This heterophilic interaction is vital for the formation of the "immunological synapse," where it provides co-stimulatory signals that enhance T-cell activation and proliferation. Consequently, dysregulation of this axis is often implicated in neuroinflammatory diseases and graft-versus-host disease (GvHD).

ALCAM Analysis Service

Are you currently facing challenges in identifying reliable biomarkers for cancer progression or navigating the complexities of cell adhesion dynamics in inflammatory diseases? Our ALCAM Analysis Services helps you achieve definitive diagnostic insights and accelerate therapeutic development through our proprietary high-sensitivity detection platforms and comprehensive antibody characterization techniques. Creative Biolabs provides the precision required to transform raw biological data into actionable clinical intelligence.

Contact our team to get an inquiry now!

Introduction of ALCAM: A Pivotal Checkpoint in Cell Adhesion and Malignancy

Activated Leukocyte Cell Adhesion Molecule (ALCAM), also designated as CD166, is a 100-105 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. Structurally, it comprises five extracellular Ig-like domains (2V + 3C), a single transmembrane span, and a short cytoplasmic tail. As a mediator of both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) interactions, it plays a fundamental role in stabilizing the immunological synapse and governing trans-endothelial migration.

Fig.1 Schematic of ALCAM structure and interactions between and within cells. (OA Literature) Fig.1 ALCAM structure and interactions between and within cells.¹

Extensive literature indicates that ALCAM expression is frequently dysregulated in various malignancies, including melanoma, prostate cancer, breast cancer, and colorectal carcinoma. Research highlights its dual role: while membrane-bound ALCAM facilitates cell-cell clustering, the proteolytic shedding of its extracellular domain (sALCAM) by metalloproteinases like ADAM17 is often a harbinger of epithelial-to-mesenchymal transition (EMT) and metastatic dissemination. Clinically, high levels of sALCAM in serum have been correlated with poor prognosis and chemoresistance. Understanding the spatial and temporal distribution of ALCAM is therefore essential for researchers aiming to inhibit tumor intravasation or enhance T-cell mediated immune responses.

Application: Diverse Utilities of ALCAM Analysis

The versatility of ALCAM as a biomarker and therapeutic target opens multiple avenues for biopharmaceutical research:

Oncology Biomarker Discovery

Quantitative assessment of ALCAM levels in tissue biopsies and liquid biopsies (serum/plasma) to correlate with tumor staging and patient survival rates.

Immune Checkpoint Research

Investigating the ALCAM-CD6 axis to modulate T-cell activation and proliferation in autoimmune disorders and graft-versus-host disease (GvHD).

Stem Cell Characterization

Utilizing ALCAM as a surface marker for the identification and isolation of mesenchymal stem cells (MSCs) and hematopoietic stem cells.

Drug Delivery Systems

Developing ALCAM-targeted antibody-drug conjugates (ADCs) or chimeric antigen receptor (CAR)-T cells for selective elimination of CD166-positive tumor cells.

Blood-Brain Barrier (BBB) Studies

Analyzing ALCAM's role in leukocyte infiltration into the central nervous system during neuroinflammatory processes.

Service Highlights

Creative Biolabs offers a specialized suite of ALCAM analysis tools designed to exceed industry standards for accuracy and reproducibility.

Unrivaled Sensitivity: Our platforms detect picogram levels of soluble ALCAM, ensuring that even early-stage changes in patient samples are captured reliably.
Validated Antibody Library: We utilize a vast collection of high-affinity antibodies targeting specific epitopes of the V and C domains, facilitating nuanced mapping of ALCAM isoforms.
Multi-Omics Integration: Beyond protein expression, we provide correlative analysis involving mRNA expression and ADAM-mediated shedding kinetics (Published Data).
Customized Assay Development: From immunohistochemistry (IHC) to high-throughput ELISA and flow cytometry, we tailor every protocol to your specific sample matrix.

Service Workflow

01Sample Preparation and Quality Control

Upon receipt, samples undergo standardized extraction or processing. We verify protein integrity and concentration using micro-BCA assays to ensure optimal input for downstream analysis.

02Primary Analysis (Detection & Quantification)

Depending on the goal, we perform IHC for spatial localization or sandwich ELISA for absolute quantification of sALCAM. This stage defines the baseline expression profile of your targets.

03Advanced Characterization (Binding Kinetics & Interaction)

We utilize Surface Plasmon Resonance (SPR) to measure the binding affinity of your lead compounds or endogenous ligands to the ALCAM extracellular domain, providing K_D values essential for therapeutic modeling.

04Data Validation and Statistical Correlation

All results are validated against internal positive/negative controls. We perform comparative analysis against "Published Data" to contextualize your findings within the broader scientific landscape.

05Final Consultation and Technical Report

You receive a detailed dossier containing high-resolution images, quantitative charts, and a summary of findings interpreted by our senior biology specialists.

FAQs

What are the biological consequences of ALCAM ectodomain shedding?

Proteolytic cleavage of the ALCAM extracellular domain is primarily mediated by metalloproteinases such as ADAM17 and MMP14. This shedding results in a transition from a pro-adhesive membrane-bound state to a migratory phenotype. High concentrations of the resulting soluble ALCAM (sALCAM) in biofluids often correlate with tumor invasiveness, as the loss of membrane anchors facilitates the detachment of malignant cells from the primary tumor mass.
How do alternative splice variants like ALCAM-Iso2 influence cancer progression?

ALCAM-Iso2 is a common splice variant characterized by a shorter stalk region due to the exclusion of exon 13. Research suggests that ALCAM-Iso2 is significantly more susceptible to enzymatic shedding than the standard ALCAM-Iso1. The resulting increase in sALCAM production disrupts stable homotypic interactions, thereby promoting cell motility and metastatic dissemination in cancers such as bladder carcinoma.
Is ALCAM expression restricted to pathological tissues?

No, ALCAM is physiologically expressed in a variety of healthy tissues, including epithelial cells, activated T cells, neurons, and fibroblasts. It plays essential roles in embryogenesis, hematopoiesis, and the stabilization of the immunological synapse. Pathological concern arises when there is a significant shift in its spatial localization (e.g., from membrane to cytoplasm) or an aberrant upregulation in specific cancer-initiating cells.
What role does glycosylation play in ALCAM's molecular weight and function?

Although the calculated molecular weight of the ALCAM protein backbone is approximately 65 kDa, it typically appears at 100-105 kDa on a Western blot due to extensive N-linked and O-linked glycosylation. These carbohydrate modifications are critical for its adhesive avidity; for instance, the presence of β1-6 branched N-glycans has been linked to increased metastatic potential in melanoma models.
How does the ALCAM-CD6 interaction affect immune signaling?

ALCAM functions as a high-affinity ligand for CD6, a marker expressed on the surface of T cells. This heterophilic interaction is vital for the formation of the "immunological synapse," where it provides co-stimulatory signals that enhance T-cell activation and proliferation. Consequently, dysregulation of this axis is often implicated in neuroinflammatory diseases and graft-versus-host disease (GvHD).

Creative Biolabs is committed to providing world-class ALCAM Analysis Services that bridge the gap between basic research and clinical application. By leveraging our deep expertise in cell adhesion molecules and advanced analytical platforms, we help you de-risk your drug development pipeline and uncover the full potential of your biological targets.

Reference

Yang, Yiming et al. "The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers." Cancers vol. 13,20 5187. 15 Oct. 2021, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers13205187